Insight Molecular Diagnostics Q1 loss narrows as costs drop

Insight Molecular Diagnostics

13/05/2026 21:22

Overview

Diagnostics technology firm's Q1 revenue missed analyst expectations, remains pre-revenue as kit sales await FDA approval

Adjusted net loss for Q1 was $9.6 mln as R&D expenses declined sequentially

Company highlighted progress toward commercialization and new research-use orders

Outlook

Company expects FDA marketing authorization for GraftAssureDx later in 2026

Insight Molecular Diagnostics anticipates significant U.S. orders after FDA authorization

Company targets regulatory approval in U.K. and E.U. in coming months

Result Drivers

R&D PRIORITIES - Co said laboratory staff focused on research and development for FDA submission, limiting revenue-generating activities

NO KIT SALES - Co did not realize any kitted product revenue in Q1 and does not expect material kit sales until after regulatory authorization

RESEARCH-USE ORDERS - Co booked initial research-use-only orders from E.U. and expects APAC order soon; described as immaterial to revenue

Company press release: ID:nGNX1zSlXZ

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Revenue
Miss
$32,000
$300,000 (3 Analysts)
Q1 Net Income
-$4.29 mln
Q1 Pretax Profit
-$4.29 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Insight Molecular Diagnostics Inc is $9.00, about 80.7% above its May 12 closing price of $4.98

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)